Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HCC1143 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 0.533 | uM | 14829.203 | 0.0460 | -0.8217 | 1.2743 | |
| HCC1143 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 2.67 | uM | 14829.203 | 0.0193 | -0.9098 | 1.2743 | |
| HCC1143 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 2.67 | uM | 14829.203 | 0.0193 | -0.9098 | 1.2743 | |
| HCC1143 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 13.3 | uM | 14829.203 | 0.0179 | -0.9150 | 1.2743 | |
| HCC1143 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 13.3 | uM | 14829.203 | 0.0179 | -0.9150 | 1.2743 | |
| HCC1143 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 66.7 | uM | 14829.203 | 0.0155 | -0.9240 | 1.2743 | |
| HCC1143 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 66.7 | uM | 14829.203 | 0.0155 | -0.9240 | 1.2743 | |
| HCC1143 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 0.000171 | uM | 14900.203 | 0.9676 | 0.9475 | 1.2372 | |
| HCC1143 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 0.000171 | uM | 14900.203 | 0.9676 | 0.9475 | 1.2372 | |
| HCC1143 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 0.000853 | uM | 14900.203 | 0.9532 | 0.9240 | 1.2372 | |
| HCC1143 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 0.000853 | uM | 14900.203 | 0.9532 | 0.9240 | 1.2372 | |
| HCC1143 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 0.00427 | uM | 14900.203 | 0.7045 | 0.5069 | 1.2372 | |
| HCC1143 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 0.00427 | uM | 14900.203 | 0.7045 | 0.5069 | 1.2372 | |
| HCC1143 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 0.0213 | uM | 14900.203 | 0.3593 | -0.1255 | 1.2372 | |
| HCC1143 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 0.0213 | uM | 14900.203 | 0.3593 | -0.1255 | 1.2372 | |
| HCC1143 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 0.107 | uM | 14900.203 | 0.1051 | -0.6763 | 1.2372 | |
| HCC1143 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 0.107 | uM | 14900.203 | 0.1051 | -0.6763 | 1.2372 | |
| HCC1143 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 0.533 | uM | 14900.203 | 0.0575 | -0.8011 | 1.2372 | |
| HCC1143 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 0.533 | uM | 14900.203 | 0.0575 | -0.8011 | 1.2372 | |
| HCC1143 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 2.67 | uM | 14900.203 | 0.0256 | -0.8968 | 1.2372 | |
| HCC1143 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 2.67 | uM | 14900.203 | 0.0256 | -0.8968 | 1.2372 | |
| HCC1143 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 13.3 | uM | 14900.203 | 0.0206 | -0.9132 | 1.2372 | |
| HCC1143 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 13.3 | uM | 14900.203 | 0.0206 | -0.9132 | 1.2372 | |
| HCC1143 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 66.7 | uM | 14900.203 | 0.0199 | -0.9156 | 1.2372 | |
| HCC1143 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 66.7 | uM | 14900.203 | 0.0199 | -0.9156 | 1.2372 |